SDC2 and acute respiratory distress syndrome: The same finding was recently published by a team from United Kingdom of Great Britain and Northern Ireland in a randomised double-blind trial involving 60 patients with moderate-to-severe COVID-related ARDS, 30 of whom received an intravenous injection of 400 million CD362-enriched umbilical cord-derived MSCs versus placebo (29).